FCCC LOGO Faculty Publications
Liang HH , Wu H , Giorgadze TA , Sariya D , Bellucci KSW , Veerappan R , Liegl B , Acs G , Elenitsas R , Shukla S , Youngberg GA , Coogan PS , Pasha T , Zhang PJ , Xu XW
Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin
American Journal of Surgical Pathology. 2007 Feb;31(2) :304-310
PMID: ISI:000243831400018   
Back to previous list
Distinction of primary skin adnexal carcinomas from cutaneous metastasis of adenocarcinomas is challenging. In this study, we evaluated podoplanin immunoreactivity in a series of primary skin adnexal tumors and adenocarcinomas metastatic to skin using a D2-40 antibody. The initial test series were composed of a total of 93 cases including 32 primary skin adnexal carcinomas, 46 benign primary adnexal tumors, and 15 cutaneous metastatic adenocarcinomas. We found that variable D2-40 reactivity was seen in all of the primary cutaneous carcinomas including sebaceous carcinomas (10/10), squamous cell carcinomas (10/10), porocarcinomas (4/4), trichilemmal carcinomas (4/4), skin adnexal carcinomas not otherwise specified (4/4), and in the majority of benign skin adnexal tumors. In contrast, no podoplanin immunoreactivity was seen in any of the 15 (0/15) cutaneous metastases. To confirm the initial findings and to further explore the utility of podoplanin reactivity in the distinction of these tumors, we also examined a test set of 35 unknown cases, including 21 adenocarcinomas metastatic to skin and 14 primary adnexal tumors, in a blinded fashion. In this test set of cases, podoplanin was negative in 22 cases and positive in 13 cases. Of the 22 podoplanin negative cases, 20 were proven to be metastatic adenocarcinoma. Of the 13 D2-40 positive cases, 12 were proven to be primary adnexal tumors. Our results suggest that podoplanin can be a useful tool to distinguish primary skin adnexal carcinomas form adenocarcinomas metastatic to skin with high sensitivity (94.5%) and specificity (97.2%).
ISI Document Delivery No.: 130XD Times Cited: 0 Cited Reference Count: 30 Cited References: BROWNSTEIN MH, 1972, CANCER, V29, P1298 CHU AY, 2005, MODERN PATHOL, V18, P105 CHU PGG, 2002, MODERN PATHOL, V15, P6 COTSARELIS G, 1989, CELL, V57, P201 COTSARELIS G, 1990, CELL, V61, P1329 CURY PM, 2000, MODERN PATHOL, V13, P107 DEBELENKO LV, 2005, MODERN PATHOL, V18, P1454 DUMOFF KL, 2005, MODERN PATHOL, V18, P97 DUMOFF KL, 2006, MODERN PATHOL, V19, P708 FOGT F, 2004, ONCOL REP, V11, P47 FRANCHI A, 2004, CANCER, V101, P973 FUKUNAGA M, 2005, HISTOPATHOLOGY, V46, P396 GALAMBOS C, 2005, PEDIATR DEVEL PATHOL, V8, P181 GIORGADZE TA, 2004, J CUTAN PATHOL, V31, P672 GOMBOS Z, 2005, CLIN CANCER RES, V11, P8364 HEALEY PM, 1991, CANCER SKIN, P347 HIRAKAWA S, 2003, AM J PATHOL, V162, P575 HONG YK, 2002, DEV DYNAM, V225, P351 JIH DM, 1999, J CUTAN PATHOL, V26, P113 KAHN HJ, 2002, MODERN PATHOL, V15, P434 KAUFMANN O, 2001, AM J CLIN PATHOL, V116, P823 KRATHEN RA, 2003, SOUTH MED J, V96, P164 MARKS A, 1999, BRIT J CANCER, V80, P569 NIAKOSARI F, 2005, ARCH DERMATOL, V141, P440 ORDONEZ NG, 1998, AM J SURG PATHOL, V22, P1215 ORDONEZ NG, 2005, HUM PATHOL, V36, P372 QURESHI HS, 2004, J CUTAN PATHOL, V31, P145 ROY S, 2005, ACTA NEUROPATHOL, V109, P497 SCHACHT V, 2005, AM J PATHOL, V166, P913 TAYLOR G, 2000, CELL, V102, P451